Maeda K, Taniwaki K, Santo T, Itsukuma T, Ito M, Anan K, Misawa M, Ohe Y, Kai S, Hara H
Department of Transfusion Medicine, Hyogo College of Medicine, Japan.
Transfusion. 1995 Aug;35(8):635-9. doi: 10.1046/j.1537-2995.1995.35895357893.x.
Recently, anti-A and/or anti-B produced by B cells from donor marrow could not be detected for more than 20 weeks in some patients who had undergone ABO-incompatible bone marrow transplantation (BMT).
Twelve to 72 weeks after 11 patients underwent ABO-incompatible BMT, titers of anti-A and anti-B were assayed, A and B antigens were identified by routine methods and flow cytometry, direct and indirect antiglobulin tests were performed, and the red cell antibody was eluted.
In some patients who underwent ABO-incompatible BMT, anti-A and/or anti-B produced by the B cells from the donor marrow could not be detected after BMT when red cells taken from the patients before BMT carried the corresponding antigen--that is, when hematopoiesis had already changed the cells to the donor's type according to ABO blood typing. Furthermore, some blood samples from those patients gave positive results in direct antiglobulin tests. Blood typing of patients after BMT showed mixed-field agglutination. In one patient, the half-life of red cells assayed with 51Cr was 22.4 days (30.0 +/- 4.0 days for normal controls).
Although many hypotheses could be considered to explain the present data, the possibility is proposed that anti-A and/or anti-B in the sera must have been consumed in some patients who underwent ABO-incompatible BMT. This may lead to problems such as difficulty of ABO typing, positive direct antiglobulin tests, and a relatively short life span of red cells.
最近,在一些接受ABO血型不合骨髓移植(BMT)的患者中,供体骨髓B细胞产生的抗A和/或抗B在20周以上无法检测到。
11例患者接受ABO血型不合BMT后12至72周,检测抗A和抗B滴度,通过常规方法和流式细胞术鉴定A和B抗原,进行直接和间接抗球蛋白试验,并洗脱红细胞抗体。
在一些接受ABO血型不合BMT的患者中,当移植前患者红细胞携带相应抗原时,即造血已根据ABO血型将细胞转变为供体类型后,移植后无法检测到供体骨髓B细胞产生的抗A和/或抗B。此外,这些患者的一些血样直接抗球蛋白试验呈阳性。移植后患者的血型显示混合视野凝集。在一名患者中,用51Cr检测的红细胞半衰期为22.4天(正常对照为30.0±4.0天)。
尽管可以考虑许多假说来解释目前的数据,但提出一种可能性,即在一些接受ABO血型不合BMT的患者中,血清中的抗A和/或抗B一定已被消耗。这可能导致诸如ABO血型鉴定困难、直接抗球蛋白试验阳性以及红细胞寿命相对较短等问题。